<?xml version="1.0" encoding="UTF-8"?>
<ref id="R35">
 <label>35</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Pertejo-Fernandez</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Ricciuti</surname>
    <given-names>B</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hammond</surname>
    <given-names>SP</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection</article-title>. 
  <source>Lung Cancer</source>
  <year>2020</year>;
  <volume>145</volume>:
  <elocation-id>S0169-5002(20)30310-X</elocation-id>:
  <fpage>181</fpage>â€“
  <lpage>5</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.lungcan.2020.02.013</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32423643?>
 </mixed-citation>
</ref>
